0 439

Cited 5 times in

ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma

 M R Yun  ;  H M Choi  ;  H N Kang  ;  Yw Lee  ;  H-S Joo  ;  D H Kim  ;  H R Kim  ;  M H Hong  ;  S O Yoon  ;  B C Cho 
 ONCOGENE, Vol.37(3) : 377-388, 2018 
Journal Title
Issue Date
Aminopyridines/pharmacology* ; Aminopyridines/therapeutic use ; Animals ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Autocrine Communication/drug effects ; Carcinoma, Squamous Cell/drug therapy* ; Carcinoma, Squamous Cell/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Drug Resistance, Neoplasm* ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Female ; Head and Neck Neoplasms/drug therapy* ; Head and Neck Neoplasms/pathology ; Humans ; Interleukin-6/genetics ; Interleukin-6/metabolism* ; MAP Kinase Signaling System/drug effects ; Mice ; Mice, Inbred NOD ; Morpholines/pharmacology* ; Morpholines/therapeutic use ; Phosphatidylinositol 3-Kinases/antagonists & inhibitors* ; Phosphatidylinositol 3-Kinases/metabolism ; Protein Kinase Inhibitors/pharmacology* ; Protein Kinase Inhibitors/therapeutic use ; Pyridones/pharmacology ; Pyridones/therapeutic use ; Pyrimidinones/pharmacology ; Pyrimidinones/therapeutic use ; RNA, Small Interfering/metabolism ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/metabolism ; STAT3 Transcription Factor/metabolism ; Squamous Cell Carcinoma of Head and Neck ; Xenograft Model Antitumor Assays
Hyperactivation of phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in head and neck squamous cell carcinoma (HNSCC). However, clinical outcomes of targeting the PI3K pathway have been underwhelming. In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC. Treatment of NVP-BKM120, a pan-PI3K inhibitor, led to upregulation of interleukin-6 (IL-6) and subsequent activation of either extracellular signal-regulated kinase (ERK) or signal transducers and activators of transcription 3 (STAT3), causing modest antitumor effects on the growth of HNSCC cells. Blockade of autocrine IL-6 signaling with siRNA or neutralizing antibody for IL-6 receptor (IL-6R) completely abolished NVP-BKM120-induced activation of ERK and STAT3 as well as expression of c-Myc oncogene, which resulted in enhanced sensitivity to NVP-BKM120. Moreover, when compared with a pharmacologic inhibitor or silencing of STAT3, trametinib, a MEK inhibitor, in combination with NVP-BKM120 yielded more potent anti-proliferative effects by inhibiting S phase transition, arresting cells at G0/G1 phase, and downregulating IL-6 and c-Myc expression. Furthermore, as compared with either agent alone, combination of NVP-BKM120 with trametinib or tocilizumab, a humanized anti-IL-6R antibody, significantly suppressed tumor growth in NVP-BKM120-resistant patient-derived tumor xenograft (PDTX) models, which was also confirmed in PDTX-derived cell lines. Collectively, these results suggested that IL-6/ERK signaling is closely involved in adaptive resistance of NVP-BKM120 in HNSCC cells, providing a rationale for a novel combination therapy to overcome resistance to PI3K inhibitors.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kang, Han Na(강한나)
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Yun, Mi Ran(윤미란)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
Hong, Min Hee(홍민희) ORCID logo https://orcid.org/0000-0003-3490-2195
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.